$45.00
2.18% today
Nasdaq, Apr 02, 10:13 pm CET
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Mirum Pharmaceuticals Inc Stock price

$45.00
-0.99 2.15% 1M
+3.51 8.46% 6M
+3.65 8.83% YTD
+19.79 78.50% 1Y
+20.93 86.95% 3Y
+31.96 245.09% 5Y
+31.79 240.65% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.96 2.18%
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Key metrics

Market capitalization $2.16b
Enterprise Value $2.20b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 235.37
EV/Sales (TTM) EV/Sales 6.52
P/S ratio (TTM) P/S ratio 6.41
P/B ratio (TTM) P/B ratio 9.43
Revenue growth (TTM) Revenue growth 80.76%
Revenue (TTM) Revenue $336.89m
EBIT (operating result TTM) EBIT $-87.61m
Free Cash Flow (TTM) Free Cash Flow $9.33m
Cash position $280.32m
EPS (TTM) EPS $-1.85
P/E forward negative
P/S forward 5.05
EV/Sales forward 5.13
Short interest 14.83%
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
337 337
81% 81%
100%
- Direct Costs 82 82
84% 84%
24%
255 255
80% 80%
76%
- Selling and Administrative Expenses 179 179
32% 32%
53%
- Research and Development Expense 140 140
37% 37%
42%
-64 -64
33% 33%
-19%
- Depreciation and Amortization 24 24
114% 114%
7%
EBIT (Operating Income) EBIT -88 -88
18% 18%
-26%
Net Profit -88 -88
45% 45%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Neutral
Business Wire
6 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.
Positive
Seeking Alpha
9 days ago
Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven ...
Neutral
Business Wire
23 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website www.mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today